Literature DB >> 10467503

Treatment of pyoderma faciale with isotretinoin in a patient with ulcerative colitis.

T Rosen1, R P Unkefer.   

Abstract

The explosive onset of fluctuant facial papulonodules, usually in young women, is characteristic of pyoderma faciale. This disorder is neither a true pyoderma nor a variant of acne, but rather a severe form of rosacea. The most effective therapeutic modality appears to be isotretinoin, especially if preceded by a brief course of oral corticosteroids or a short interval of application of potent topical corticosteroids. Despite our concern about the potential adverse effects of systemic retinoids on underlying inflammatory bowel disease, isotretinoin was given to a patient with refractory pyoderma faciale. Response was dramatic, and no ill effects were encountered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10467503

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  5 in total

1.  Use of oral isotretinoin in the management of rosacea.

Authors:  Hyunhee Park; James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2011-09

Review 2.  Updated Physician's Guide to the Off-label Uses of Oral Isotretinoin.

Authors:  Steven Brandon Nickle; Nathan Peterson; Michael Peterson
Journal:  J Clin Aesthet Dermatol       Date:  2014-04

3.  Successful treatment of localized pyoderma faciale in a patient with Crohn's disease.

Authors:  Sanam Razeghi; Christian R Halvorson; Anthony A Gaspari; Raymond K Cross
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-08

4.  [Rosacea fulminans, pyostomatitis and pyovulvitis in Crohn's disease: dapsone as key factor in combination therapy].

Authors:  M Gatzka; M Simon; G Schuler; M Lüftl
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

Review 5.  A causal association between isotretinoin and inflammatory bowel disease has yet to be established.

Authors:  Seth D Crockett; Ajay Gulati; Robert S Sandler; Michael D Kappelman
Journal:  Am J Gastroenterol       Date:  2009-10       Impact factor: 10.864

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.